Cargando…

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer

Detalles Bibliográficos
Autor principal:	Kumar, Gautam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279108/ https://www.ncbi.nlm.nih.gov/pubmed/32549671 http://dx.doi.org/10.4103/iju.IJU_315_19

Ejemplares similares

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
por: Sharma, Aditya Prakash
Publicado: (2017)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
por: Bhargava, Priyank
Publicado: (2023)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

PROMPTS Trial: Screening spinal magnetic resonance imaging in castration-resistant prostate cancer
por: Pattnaik, Soumya Shivasis
Publicado: (2023)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

T1 bladder cancer on restaging transurethral resection should be treated with immediate cystectomy
por: Gautam, Gagan, et al.
Publicado: (2007)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

Antibiotic prophylaxis in vesicoureteral reflux: A paradigm shift
por: Banerji, J. S., et al.
Publicado: (2009)

Defining the role of antioxidants in the prevention of prostate cancer
por: Pathak, Hemant R., et al.
Publicado: (2009)

Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial
por: Dubey, Deepak, et al.
Publicado: (2008)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

The current role of Active Surveillance in early prostate cancer
por: Shrinivas, R. P., et al.
Publicado: (2009)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial
por: Tarigopula, Vivek
Publicado: (2022)

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

HERO trial: A rescue from injectable androgen deprivation therapy
por: Ranjan, Satish Kumar
Publicado: (2021)

Multiparametric magnetic resonance imaging-targeted biopsies in the detection of clinically significant prostate cancer
por: Charalampos, Fragkoulis
Publicado: (2020)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning
por: Agrawal, Sumit
Publicado: (2020)

STHLM3-MRI study: Role of magnetic resonance imaging-targeted biopsy in prostate cancer screening
por: Gaur, Abhay S.
Publicado: (2022)

Neoadjuvant androgen suppression in patients treated with high-intensity focused ultrasound therapy
por: Khochikar, Makarand V.
Publicado: (2007)

Is lap nephrectomy superior to open? A randomized trial
por: Kumar, Anup, et al.
Publicado: (2008)

Application of a fluoroscopy protocol in percutaneous nephrolithotomy to decrease radiation exposure: A feasible option
por: Choudhary, Gautam Ram
Publicado: (2014)

A novel approach to management of nocturia in patients with benign prostatic hyperplasia
por: Sengottayan, Vengetesh K., et al.
Publicado: (2009)

Optimizing bowel recovery after laparoscopic donor nephrectomy
por: Prakash, Gagan, et al.
Publicado: (2008)

Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size
por: Prakash, Gagan, et al.
Publicado: (2007)

Vaginal mucosal vaccine for recurrent urinary tract infections
por: Gautam, Gagan, et al.
Publicado: (2007)

POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_75q2m819v80j37rlchbg8l5gqf